Nasal Tumor Vaccination Protects against Lung Tumor Development by Induction of Resident Effector and Memory Anti-Tumor Immune Responses

Date

2023-02-26

Authors

Donkor, Michael
Choe, Jamie Y.
Reid, Danielle
Quinn, Byron
Pulse, Mark
Ranjan, Amalendu P.
Chaudhary, Pankaj
Jones, Harlan P.

ORCID

0000-0003-3248-0355 (Jones, Harlan P.)
0000-0003-0518-4120 (Chaudhary, Pankaj)
0000-0002-3641-7751 (Ranjan, Amalendu P.)
0000-0002-7803-5962 (Choe, Jamie Y.)
0000-0002-5488-0328 (Donkor, Michael)

Journal Title

Journal ISSN

Volume Title

Publisher

MDPI

Abstract

Lung metastasis is a leading cause of cancer-related deaths. Here, we show that intranasal delivery of our engineered CpG-coated tumor antigen (Tag)-encapsulated nanoparticles (NPs)-nasal nano-vaccine-significantly reduced lung colonization by intravenous challenge of an extra-pulmonary tumor. Protection against tumor-cell lung colonization was linked to the induction of localized mucosal-associated effector and resident memory T cells as well as increased bronchiolar alveolar lavage-fluid IgA and serum IgG antibody responses. The nasal nano-vaccine-induced T-cell-mediated antitumor mucosal immune response was shown to increase tumor-specific production of IFN-gamma and granzyme B by lung-derived CD8(+) T cells. These findings demonstrate that our engineered nasal nano-vaccine has the potential to be used as a prophylactic approach prior to the seeding of tumors in the lungs, and thereby prevent overt lung metastases from existing extra pulmonary tumors.

Description

Citation

Donkor, M., Choe, J., Reid, D. M., Quinn, B., Pulse, M., Ranjan, A., Chaudhary, P., & Jones, H. P. (2023). Nasal Tumor Vaccination Protects against Lung Tumor Development by Induction of Resident Effector and Memory Anti-Tumor Immune Responses. Pharmaceutics, 15(2), 445. https://doi.org/10.3390/pharmaceutics15020445

Rights

© 2023 by the authors.

License

Attribution 4.0 International (CC BY 4.0)